HIV Infections
Conditions
Brief summary
This study will evaluate: (1) the effect of co-administration of single doses of calcium carbonate antacid and magnesium/aluminum hydroxide antacid on the steady-state plasma pharmacokinetic profile of raltegravir in human immunodeficiency virus (HIV)-infected participants; and (2) the effect of staggered dosing of a single dose of a magnesium/aluminum hydroxide antacid 2 hours before and 2 hours after administration of raltegravir on the steady-state plasma pharmacokinetic profile of raltegravir in the same participants. The study will determine whether (1) the C12hrs of steady-state raltegravir after co-administration of single doses of calcium carbonate antacid is decreased to a clinically meaningful degree compared with C12hrs after administration of raltegravir alone; and whether (2) the C12hrs of steady-state raltegravir after co-administration of a single dose of magnesium/aluminum hydroxide antacid is decreased to a clinically meaningful degree compared with the C12hrs after administration of raltegravir alone.
Interventions
DRUGRaltegravir
Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
DRUGTUMS® Ultra Strength
3 tablets TUMS® Ultra Strength (US) 1000 mg Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
DRUGMINTOX® Maximum Strength
20 mL MINTOX® Maximum Strength (MS) Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-infected participant on a stable raltegravir dose (400 mg every 12 hours) as part of a stable anti-retroviral regimen (ARV) for at least 1 month and will maintain current ARV therapy throughout the study * Body Mass Index ≤32 kg/m\^2 * Good general health * Can be a current smoker and/or user of nicotine or nicotine-containing products, but use of nicotine-containing products will not be permitted during the stay at the clinical research site
Exclusion criteria
* History of gastric bypass surgery * Pregnant or nursing * Mentally or legally incapacitated, has significant emotional problems, or has a history of a clinically significant psychiatric disorder; participants who have had situational depression may be enrolled at the discretion of the investigator. * History of stroke, chronic seizures, or major neurological disorder * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases (excluding HIV); participants with a history of uncomplicated kidney stones or childhood asthma may be enrolled at the discretion of the investigator. * Active neoplastic disease deemed unstable or progressing by the investigator * Currently taking rifampin or unable to refrain from use of any proton pump inhibitor and any histamine-2 (H2)-blockers, over-the-counter antacids, calcium supplements, or multivitamins during the study * Consumes excessive amounts of alcohol * Consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages * Major surgery or blood donation within the past 4 weeks * History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food * Regular user of any illicit drugs or history of drug (including alcohol) abuse within the past 6 months; current methadone or suboxone use is allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 12 hours postdose | Participant blood samples were collected to measure the steady state plasma concentration of raltegravir 12 hours after administration alone or with a single dose of antacid. The primary hypothesis compared C12hrs of raltegravir when administered alone with C12hrs of raltegravir when coadministered with TUMS® or MINTOX®. |
| Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 12 hours postdose | Participant blood samples were collected to measure the steady state plasma concentration of raltegravir 12 hours after administration alone or before or after a single dose of antacid. The secondary hypothesis compared C12hrs of raltegravir when administered alone with C12hrs of raltegravir when administered 2 hours before or after MINTOX®. |
| Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose | Participant blood samples were collected to measure the steady state AUC of raltegravir up to 12 hours after administration alone or with a single dose of antacid. The primary hypothesis compared AUC0-12hrs of raltegravir when administered alone with AUC0-12hrs of raltegravir when coadministered with TUMS® or MINTOX®. |
| Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose | Participant blood samples were collected to measure the steady state AUC of raltegravir up to 12 hours after administration alone or before or after a single dose of antacid. The secondary hypothesis compared AUC0-12hrs of raltegravir when administered alone with AUC0-12hrs of raltegravir when administered 2 hours before or after MINTOX®. |
| Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose | Participant blood samples were collected to measure the steady state maximum plasma concentration of raltegravir when administered alone or with a single dose of antacid. The primary hypothesis compared Cmax of raltegravir when administered alone with Cmax of raltegravir when coadministered with TUMS® or MINTOX®. |
| Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose | Participant blood samples were collected to measure the maximum steady state plasma concentration of raltegravir after administration alone or before or after a single dose of antiacid. The secondary hypothesis compared Cmax of raltegravir when administered alone with Cmax of raltegravir when administered 2 hours before or after MINTOX®. |
| Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose | Participant blood samples were collected to measure the time to achieve the maximum steady state plasma concentration of raltegravir when administered alone or with a single dose of antacid |
| Number of Participants With Any Clinical or Laboratory Adverse Event (AE) | Up to 7 days after the last dose of study drug | An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a 2-day washout between treatment periods. | 4 |
| TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods. | 5 |
| MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods. | 4 |
| RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods. | 6 |
| TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods. | 4 |
| MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods. | 4 |
| Total | 27 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Treatment Period 1 | Protocol Violation | 0 | 1 | 0 | 0 | 0 | 0 |
| Treatment Period 1 | Withdrawal by Subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Treatment Period 2 | Withdrawal by Subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Treatment Period 3 | Protocol Violation | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL | Total | RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL | TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL | MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL | RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL | TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 40.8 years STANDARD_DEVIATION 11.6 | 41.3 years STANDARD_DEVIATION 10.7 | 42.5 years STANDARD_DEVIATION 10.4 | 46.6 years STANDARD_DEVIATION 9.5 | 36.8 years STANDARD_DEVIATION 15.4 | 40.3 years STANDARD_DEVIATION 10.3 | 39.8 years STANDARD_DEVIATION 11.8 |
| Sex: Female, Male Female | 0 Participants | 5 Participants | 2 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants |
| Sex: Female, Male Male | 4 Participants | 22 Participants | 2 Participants | 4 Participants | 4 Participants | 4 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 26 | 0 / 25 | 0 / 25 | 0 / 23 | 0 / 23 |
| serious Total, serious adverse events | 0 / 26 | 0 / 25 | 0 / 25 | 0 / 23 | 0 / 23 |
Outcome results
Primary
Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)
Participant blood samples were collected to measure the steady state maximum plasma concentration of raltegravir when administered alone or with a single dose of antacid. The primary hypothesis compared Cmax of raltegravir when administered alone with Cmax of raltegravir when coadministered with TUMS® or MINTOX®.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose
Population: All participants were included for whom at least one PK parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Raltegravir | Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 5427.15 nM | 95% Confidence Interval 4530 |
| TUMS® + Raltegravir | Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 2584.78 nM | 95% Confidence Interval 1700 |
| MINTOX® + Raltegravir | Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 3013.88 nM | 95% Confidence Interval 1940 |
90% CI: [0.362, 0.627]Mixed Models Analysis
95% CI: [0.423, 0.729]Mixed Models Analysis
Primary
Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)
Participant blood samples were collected to measure the maximum steady state plasma concentration of raltegravir after administration alone or before or after a single dose of antiacid. The secondary hypothesis compared Cmax of raltegravir when administered alone with Cmax of raltegravir when administered 2 hours before or after MINTOX®.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose
Population: All participants were included for whom at least one PK parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Raltegravir | Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 5678.90 nM |
| TUMS® + Raltegravir | Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 2753.64 nM |
| MINTOX® + Raltegravir | Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 4399.66 nM |
90% CI: [0.332, 0.709]Mixed Models Analysis
90% CI: [0.53, 1.132]Mixed Models Analysis
Primary
Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)
Participant blood samples were collected to measure the steady state AUC of raltegravir up to 12 hours after administration alone or before or after a single dose of antacid. The secondary hypothesis compared AUC0-12hrs of raltegravir when administered alone with AUC0-12hrs of raltegravir when administered 2 hours before or after MINTOX®.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose
Population: All participants were included for whom at least one PK parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Raltegravir | Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 17577.15 nM*hr |
| TUMS® + Raltegravir | Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 8521.95 nM*hr |
| MINTOX® + Raltegravir | Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 12226.11 nM*hr |
90% CI: [0.351, 0.669]Mixed Models Analysis
90% CI: [0.504, 0.96]Mixed Models Analysis
Primary
Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)
Participant blood samples were collected to measure the steady state AUC of raltegravir up to 12 hours after administration alone or with a single dose of antacid. The primary hypothesis compared AUC0-12hrs of raltegravir when administered alone with AUC0-12hrs of raltegravir when coadministered with TUMS® or MINTOX®.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose
Population: All participants were included for whom at least one PK parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Raltegravir | Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 16399.76 nM*hr | 95% Confidence Interval 12300 |
| TUMS® + Raltegravir | Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 7294.30 nM*hr | 95% Confidence Interval 6690 |
| MINTOX® + Raltegravir | Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 8358.67 nM*hr | 95% Confidence Interval 5040 |
90% CI: [0.35, 0.565]Mixed Models Analysis
90% CI: [0.402, 0.646]Mixed Models Analysis
Primary
Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)
Participant blood samples were collected to measure the steady state plasma concentration of raltegravir 12 hours after administration alone or with a single dose of antacid. The primary hypothesis compared C12hrs of raltegravir when administered alone with C12hrs of raltegravir when coadministered with TUMS® or MINTOX®.
Time frame: 12 hours postdose
Population: All participants were included for whom at least one pharmacokinetic (PK) parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Raltegravir | Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 132.30 nM | 95% Confidence Interval 112 |
| TUMS® + Raltegravir | Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 89.75 nM | 95% Confidence Interval 134 |
| MINTOX® + Raltegravir | Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) | 49.38 nM | 95% Confidence Interval 32.6 |
90% CI: [0.531, 0.866]Mixed Models Analysis
90% CI: [0.293, 0.475]Mixed Models Analysis
Primary
Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)
Participant blood samples were collected to measure the steady state plasma concentration of raltegravir 12 hours after administration alone or before or after a single dose of antacid. The secondary hypothesis compared C12hrs of raltegravir when administered alone with C12hrs of raltegravir when administered 2 hours before or after MINTOX®.
Time frame: 12 hours postdose
Population: All participants were included for whom at least one PK parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Raltegravir | Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 125.75 nM |
| TUMS® + Raltegravir | Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 54.92 nM |
| MINTOX® + Raltegravir | Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis) | 54.47 nM |
90% CI: [0.344, 0.554]Mixed Models Analysis
90% CI: [0.341, 0.55]Mixed Models Analysis
Primary
Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir
Participant blood samples were collected to measure the time to achieve the maximum steady state plasma concentration of raltegravir when administered alone or with a single dose of antacid
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose
Population: All participants were included for whom at least one PK parameter could be calculated for all treatment periods and who did not have any protocol deviation interfering with pharmacokinetics
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Raltegravir | Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir | 2.06 hr | Standard Deviation 1.23 |
| TUMS® + Raltegravir | Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir | 2.08 hr | Standard Deviation 1.64 |
| MINTOX® + Raltegravir | Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir | 1.48 hr | Standard Deviation 0.94 |
| MINTOX® Before Raltegravir | Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir | 1.52 hr | Standard Deviation 1.17 |
| MINTOX® After Raltegravir | Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir | 1.78 hr | Standard Deviation 1.37 |
Primary
Number of Participants With Any Clinical or Laboratory Adverse Event (AE)
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience.
Time frame: Up to 7 days after the last dose of study drug
Population: All subjects who received any amount of the study drug were included in the safety population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Raltegravir | Number of Participants With Any Clinical or Laboratory Adverse Event (AE) | 1 participants |
| TUMS® + Raltegravir | Number of Participants With Any Clinical or Laboratory Adverse Event (AE) | 2 participants |
| MINTOX® + Raltegravir | Number of Participants With Any Clinical or Laboratory Adverse Event (AE) | 2 participants |
| MINTOX® Before Raltegravir | Number of Participants With Any Clinical or Laboratory Adverse Event (AE) | 2 participants |
| MINTOX® After Raltegravir | Number of Participants With Any Clinical or Laboratory Adverse Event (AE) | 1 participants |